AB Science SA (Euronext: AB) announced initial data from its Phase 1 study of AB8939 combined with venetoclax for treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE